Tanya Dorff, MD
Enriched profileProfessor, Department of Medical Oncology & Therapeutics Research; Division/Section Chief, Genitourinary Disease Program; Vice Chair of Clinical Affairs, City of Hope · City of Hope National Medical Center
Tanya Dorff is Professor, Department of Medical Oncology & Therapeutics Research; Division/Section Chief, Genitourinary Disease Program; Vice Chair of Clinical Affairs, City of Hope at City of Hope National Medical Center. OpenAlex indexes 642 publications with 13,907 citations (h-index 51); ClinicalTrials.gov lists 12 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Tanya Barauskas Dorff, M.D., is Professor, Department of Medical Oncology & Therapeutics Research at City of Hope National Medical Center / City of Hope Comprehensive Cancer Center (Duarte, CA). The public record shows 642 publications with 13,907 citations (h-index 51), centered on Prostate Cancer Treatment and Research, Prostate Cancer Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers. It also documents an investigator role on 12 registered clinical trials, industry payments reported by 33 companies, 2 NIH-funded awards (2022–2026).
- Most recent indexed publication: 2026 · Cancers
- Top research focus: Prostate Cancer Treatment and Research
- 12 registered trials on ClinicalTrials.gov
- Open Payments reporting from 33 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 51 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 154.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 12 registered studies on ClinicalTrials.gov. The most recent:
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
Sponsor: Canadian Cancer Trials Group
- PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
Sponsor: City of Hope Medical Center
- Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer
Sponsor: City of Hope Medical Center
Industry payments
Updated 14 Oct 2026
33 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- ABBVIE INC.Program year20258 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Blue Earth DiagnosticsProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
77.5%Gonadotropin Releasing Hormone Receptor Antagonist27.9%Orgovyx100%Part D≥63 patientsCytochrome P450 17A1 Inhibitor18.8%Abiraterone Acetate100%Part D≥40 patients+ 4 more classes in this area
Metabolism & gastrointestinal
15.1%Corticosteroid13.9%Prednisone100%Part D≥41 patientsSerotonin-3 Receptor Antagonist1.1%Ondansetron Hcl100%Part D<11 patientsNervous system
2.4%Gabapentinoids1.4%Gabapentin100%Part D<11 patientsSNRI1%Venlafaxine Hcl Er100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
2 NIH research awards on record, funded 2022–2026 per NIH RePORTER. The latest:
- Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Cedars-Sinai Medical Center
FY2026$681,082R01CA280081 - Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Cedars-Sinai Medical Center
FY2025$684,131R01CA280081 - Intermittent Fasting using a Fasting-Mimetic Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Cedars-Sinai Medical Center
FY2025$102,955R01CA280081
Congress activity
Updated 14 Oct 2026
219 congress contributions (2005–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract A075: HER2 as an Ancestry-associated Therapeutic Target in Prostate Cancer
AACR (meeting unresolved)
AACR2026Co-author - Abstract 7162: Association between circulating B cell subtypes and treatment response in patients with metastatic renal cell carcinoma (mRCC)
AACR Annual Meeting
AACR2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Comprehensive Profiling of Cell Surface Proteins in Testicular Germ Cell Tumors.
Cancer research communications
Article2026 - Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase IIa PLANETTE Study.
Cancer research communications
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyArticle1,576 citations2019
- 02
- 03Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in OncologyArticle588 citations2023
- 04
- 05NCCN Guidelines Insights: Prostate Cancer, Version 1.2021Article532 citations2021
Network
Updated 14 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- X / Twitter
x.com/TDorffOnc
- Doximity
doximity.com/pub/tanya-dorff-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- LinkedIn
linkedin.com/posts/city-of-hope_dr-tanya-dorff-shaping-tomorrows-prostate-activity-7399503834441474049-8oVP
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗ - LinkedIn
LinkedIn post by colleague Sumanta Pal, MD, FASCO praising Dr. Dorff's work at City of Hope
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - Doximity
Doximity professional profile listing (Duarte, CA; Oncology)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
UCLA School of Medicine (elected Alpha Omega Alpha)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - BS/BA
University of Houston (summa cum laude)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Internal Medicine residency
Mount Sinai Hospital (New York)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Hematology/Oncology fellowship
LAC+USC Medical Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancercenter.com ↗
Editorial & leadership roles
journal and society appointments- Associate Editor
Prostate Cancer and Prostatic Diseases (Springer Nature journal)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Associate Editor
Seminars in Urologic Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Member
NCCN Guidelines Panel for Prostate Cancer
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗ - Co-chair
Prostate Subcommittee within the SWOG Genitourinary Cancer Committee (also leads DEI efforts for the group)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →media.mycme.com ↗
Awards & honors
honors on the public record- Fellow of the American Society of Clinical Oncology (FASCO)
2026 class, cited on ASCO honor roll alongside her name/credentials in the City of Hope profile title ("M.D., F.A.S.C.O.")
2026verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →oncodaily.com ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Secondary affiliations
appointments beyond the home institution- Keck School of Medicine of the University of Southern California
Assistant then Associate Professor of Clinical Medicine, ~2008-2017/2018
2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →orcid.org ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →guoncologynow.com ↗
- Grand Rounds in Urology video interview
"Dr. Tanya Dorff On Chemotherapy For Prostate Cancer"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →grandroundsinurology.com ↗ - OncLive On Air podcast
"Safety and Quality-of-Life Considerations Shape ADT Use in Prostate Cancer: With Tanya B. Dorff, MD"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Sumanta Pal, MD
City of Hope National Medical Center
Joanne Mortimer, MD
City of Hope National Medical Center
Vinod Pullarkat, MD
City of Hope National Medical Center
Alex Herrera, MD
City of Hope National Medical Center
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)